최근 ATCC가 분석한 proteomics data 결과를 기반으로 PD-L1이 높은 수준으로 발현되어 있는 Solid tumor cell line인 “HCC827” 세포를 이용하여 IFN-γ-IFN-γR JAK-STAT GAS-Luc2 reporter system (HCC827 GAS-Luc2 cell line, Cat# CRL-2868-GAS-LUC2)이 새롭게 개발되었습니다.
Cancer cell과 CD8+T cell의 PD-1/PD-L1 interaction이 inhibition 되면 bioluminescent (luciferase) signal이 발현되는 메카니즘으로 다양한 immune check point inhibitors의 efficacy, potency 및 dynamics 등을 평가할 수 있습니다.
ATCC has generated a checkpoint luciferase reporter cell line with high expression of endogenous programmed death-ligand 1 (PD-L1). The reporter system contains a gamma interferon activation site (GAS)-response element upstream of the luciferase gene. In the presence of PD-1/PD-L1 inhibition, a bioluminescent signal is produced, which can be detected and quantified to evaluate inhibitor efficacy, potency, and dynamics. Learn how you can accelerate your next breakthrough in immuno-oncology.
Fig1. Mechanism of action. Luciferase signal generated by HCC827-GAS-Luc2 cells upon T cell activation through the PD-L1 blockade. Created with BioRender.com.
Fig2. Schematics of PD-L1-expressing GAS-Luc2 reporter Cell line. Selected cell lines with high endogenous expression of PD-L1 were transfected with lentiviral-GAS-Luc2 plasmids.
ATCC Checkpoint Luciferase Reporter Cells이 새롭게 추가되었습니다 !!! (2023_05 업데이트)
Table 1: ATCC Checkpoint Luciferase Reporter Cells | ||||||
Designation | ATCC® No. | Disease | Biomarker | Tissue of origin | Status | |
HCC827-GAS-Luc2 | CRL-2868-GAS-LUC2™ | Adenocarcinoma | PD-L1 | Lung | Available | |
MG-63-GAS-Luc2 | CRL-1427-GAS-LUC2™ | Osteosarcoma | CD-155 | Bone | Available | |
NCI-H1650-GAS-Luc2 | CRL-5883-GAS-LUC2™ | Adenocarcinoma | B7-H3 | Lung | Coming soon | |
SUP-T1 [VB]-NFAT-Luc2 | CRL-1942-NFAT-LUC2™ | Lymphoblastic Lymphoma | PD-1 T cell |
Pleural effusion | Coming soon |
자세한 내용이 궁금하시면 아래 HCC827 GAS-Luc2 cell line 관련 ATCC application Note를 다운로드 받으세요.
* 주문 및 견적 문의는 지사/대리점으로 연락 주세요
- 지사/대리점 안내Opens in a new tab